Please provide your email address to receive an email when new articles are posted on . A kidney disease panel for 382 genes yielded a high success rate and was effective in identifying monogenic ...
Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022 Demand for germline hereditary cancer genetic testing has ...
PORTLAND, Ore.--(BUSINESS WIRE)--Wisdom Panel, the world leader in pet genetics and maker of Wisdom Panel™ pet DNA tests, announced today the publication of the two largest genetic screening studies ...
Demand for germline hereditary cancer genetic testing has increased because of reduced cost, gene discovery, expanding indications, and precision cancer therapies. The traditional model for germline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results